Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with TTR-mediated Amyloid Cardiomyopathy

    NEXT STORY
    Global In-Vitro Diagnostics (IVD) Market Report, 2019-2025 – Advent of NGS has Created a Significant Opportunity for Advances in IVD Tests
    PREV STORY
    Press release Oncology Venture issues 287,500 new shares in connection with a debt conversion
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    FIT Biotech Oy: Conversion of FIT Biotech Oy’s Convertible Notes into shares

    FIT Biotech Oy Company release September 30, 2016 at 08.30 am EET Conversion of ...

    author_avatar
    NASDAQ Market News

    Microbot Medical Showcases a Working Prototype of its Self-Cleaning Shunt

    HINGHAM, Mass., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq CM: MBOT) ...

    author_avatar
    NASDAQ Market News

    Beyond Air® Announces $30 Million of Committed Capital in Previously Reported Beyond Cancer™ Private Placement

    author_avatar
    NASDAQ Market News